The impact of anticancer drugs on the ocular surface
Sign up to keep reading
Create a free Member account at NZ Optics to read this article and more.
- Read all Member articles
- Full digital magazine archive
- Early access to new articles
Artificial intelligence (AI) use in eyecare is moving fast, but are regulation, ethics and real-world integration keeping pace? As clinicians and regulators grapple with how to harness its potential without compromising patient safety or equity, Drew Jones examines where AI use in eyecare stands and
February is my favourite time of the year. Not only is there beautiful summer weather and warm seawater, but this is the time when the Australian and New Zealand Glaucoma Society (ANZGS) Congress takes place! This year’s meeting was in Sydney CBD’s Masonic Centre. It’s a fabulous venue with beautifu
In eyecare, some of the most life-changing diagnoses are also the most common. For clinicians, they sit within well‑worn management pathways. For patients, they often mean uncertainty, a loss of independence and perhaps even a life‑changing fear of blindness.
Come on tour of the Corneal Lens Corporation’s (CLC) laboratory in Christchurch